22nd September, 2000

VIA FAX AND MAIL
[0208 966 8330]

Glaxo Wellcome Plc
Blaxo Wellcome House
Berkley Avenue
Greenford
Middlesex
UB6 0NN

For the attention of G. G. Brereton, Head of Patents - Global Intellectual Property Department

Dear Sirs,

Lamivudine/Zidovudine Combinations - Ghana

We refer to your letter of 10th August 2000 addressed to Cipla Limited, which has been passed to us.

It is our understanding that three of the four ARIPO patents which you mention, namely AP11, AP136 and AP182 are unenforcable in Ghana since this country did not allow patent protection for pharmaceutical products per se until 1st July 1993 and these patents were granted before then. The fourth patent (AP300) was granted after the abovedate, but it relates only to crystalline lamivudine.

We would be grateful for your comments on the above, in particular as to which (if any) of the above ARIPO patents you belive to be enforcable in Ghana and infringed by our client's product, Duovir.

Yours faithfully

A. A. THORTON & CO